We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $15.60, marking a +2.77% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.23%. Elsewhere, the Dow gained 0.72%, while the tech-heavy Nasdaq added 1.86%.
The stock of infectious disease drug developer has fallen by 2.75% in the past month, lagging the Medical sector's gain of 4.41% and the S&P 500's gain of 2.45%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $130.1 million, showing a 8.56% escalation compared to the year-ago quarter.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $506.7 million. These results would represent year-over-year changes of +16.33% and +18.82%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 26.63. For comparison, its industry has an average Forward P/E of 20.3, which means Adma Biologics is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 92, this industry ranks in the top 38% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Adma Biologics (ADMA - Free Report) closed at $15.60, marking a +2.77% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.23%. Elsewhere, the Dow gained 0.72%, while the tech-heavy Nasdaq added 1.86%.
The stock of infectious disease drug developer has fallen by 2.75% in the past month, lagging the Medical sector's gain of 4.41% and the S&P 500's gain of 2.45%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is predicted to post an EPS of $0.16, indicating a 6.67% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $130.1 million, showing a 8.56% escalation compared to the year-ago quarter.
ADMA's full-year Zacks Consensus Estimates are calling for earnings of $0.57 per share and revenue of $506.7 million. These results would represent year-over-year changes of +16.33% and +18.82%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Adma Biologics currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 26.63. For comparison, its industry has an average Forward P/E of 20.3, which means Adma Biologics is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 92, this industry ranks in the top 38% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.